TRDA
Entrada Therapeutics, Inc. NASDAQ Listed Oct 29, 2021$6.89
Mkt Cap $267.5M
52w Low $4.93
17.0% of range
52w High $16.45
50d MA $13.02
200d MA $9.31
P/E (TTM)
-4.2x
EV/EBITDA
-2.7x
P/B
2.0x
Debt/Equity
0.2x
ROE
-47.0%
P/FCF
-3.3x
RSI (14)
—
ATR (14)
—
Beta
-0.15
50d MA
$13.02
200d MA
$9.31
Avg Volume
192.3K
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
CIK (SEC)
Phone
857 520 9158
6 Tide Street · Boston, MA 02210 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 16.03 | -57.5% | -57.3% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -1.32 | -0.94 | +28.8% | 12.79 | +1.1% | -6.7% | -8.7% | -7.3% | -2.3% | -9.1% | — |
| Nov 6, 2025 | AMC | -1.04 | -1.06 | -1.9% | 6.95 | -1.7% | -0.6% | +4.5% | +10.8% | +15.3% | +26.3% | — |
| Aug 6, 2025 | AMC | -0.86 | -1.04 | -20.9% | 5.95 | +0.0% | -10.9% | -12.8% | -15.6% | -13.3% | -10.6% | — |
| May 8, 2025 | AMC | -0.78 | -0.42 | +46.2% | 8.62 | +0.6% | -2.8% | +2.3% | +0.9% | -7.5% | -5.8% | — |
| Feb 27, 2025 | AMC | -0.66 | 0.03 | +104.5% | 11.98 | -1.5% | -0.3% | -5.4% | -8.3% | -11.7% | -13.0% | — |
| Nov 5, 2024 | AMC | -0.67 | -0.35 | +47.8% | 18.62 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% | — |
| Aug 13, 2024 | AMC | 0.14 | 1.55 | +1007.1% | 15.81 | +1.2% | +0.1% | +2.8% | +4.6% | +4.5% | +7.1% | — |
| May 7, 2024 | AMC | -0.59 | 0.68 | +215.3% | 13.88 | -2.6% | +1.2% | +3.5% | +3.3% | +1.2% | +2.2% | — |
| Mar 13, 2024 | AMC | -0.07 | -0.29 | -314.3% | 12.71 | -2.8% | -4.0% | +0.6% | -2.4% | -0.1% | +5.0% | — |
| Nov 7, 2023 | AMC | -0.74 | 1.02 | +237.8% | 16.99 | +0.1% | -0.7% | -5.2% | -2.1% | -3.5% | -0.9% | — |
| Aug 8, 2023 | AMC | -0.43 | -0.78 | -81.4% | 15.40 | +0.3% | -0.6% | +1.6% | +6.6% | -0.3% | +3.8% | — |
| May 10, 2023 | AMC | -0.77 | -0.21 | +72.7% | 11.93 | +0.3% | +1.8% | +4.8% | +7.3% | +9.6% | +13.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8 | H.C. Wainwright | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Apr 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.15 | $13.31 | +1.2% | +5.6% | +5.3% | +8.9% | +6.8% | +2.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.02 | $11.01 | -0.1% | +0.2% | +3.5% | +2.5% | +2.5% | +4.2% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $7.98 | -0.4% | +2.9% | -4.0% | -4.9% | -6.4% | -3.9% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.56 | $9.43 | -1.4% | -5.4% | -8.4% | -7.9% | -16.1% | -16.9% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.85 | $13.04 | +1.5% | -5.7% | -6.5% | -6.8% | -7.1% | -11.8% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.33 | $13.39 | +0.5% | +1.7% | +5.0% | +1.1% | -2.9% | -3.5% |
| Nov 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.62 | $19.75 | +6.1% | +0.2% | +3.3% | +6.4% | +6.8% | +6.3% |
| Aug 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $16.52 | $16.62 | +0.6% | +2.4% | +1.1% | -1.2% | +5.9% | +7.1% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.81 | $16.00 | +1.2% | +0.1% | +2.8% | +4.6% | +4.5% | +7.1% |
| Jun 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.24 | $14.15 | -0.6% | +3.7% | -1.0% | -0.5% | +0.1% | +0.6% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.78 | $12.78 | +0.0% | -2.9% | -0.6% | +4.5% | +5.9% | +7.4% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.49 | $11.51 | +0.2% | +8.8% | +10.7% | +13.3% | +12.9% | +16.6% |
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.61 | $13.56 | -0.4% | +6.0% | +9.7% | +9.3% | +13.9% | +18.9% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.40 | $15.44 | +0.3% | -0.6% | +1.6% | +6.6% | -0.3% | +3.8% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.94 | $16.82 | -0.7% | -12.1% | -14.7% | -15.9% | -17.7% | -9.1% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.32 | $13.43 | +0.8% | -4.3% | -10.5% | -11.7% | -17.3% | -14.0% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.50 | $14.62 | +0.8% | +4.8% | -0.5% | -3.7% | -4.9% | +1.7% |
| Nov 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.84 | $19.33 | -2.6% | -3.2% | -4.1% | -2.7% | -4.1% | -5.1% |
| Aug 16 | Goldman Sachs | Maintains | Neutral → Neutral | — | $12.80 | $12.59 | -1.6% | -3.1% | -0.3% | +0.8% | +1.4% | +2.5% |
| May 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $6.05 | $5.89 | -2.6% | -0.8% | +3.6% | +8.9% | +16.0% | +11.7% |
| Nov 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $24.13 | $24.52 | +1.6% | +11.9% | +19.8% | +25.6% | +23.4% | +26.3% |
| Nov 23 | Cowen & Co. | Maintains | Outperform → Outperform | — | $30.40 | $30.01 | -1.3% | -20.6% | -11.2% | -4.9% | -0.3% | -2.0% |
| Nov 23 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.40 | $30.01 | -1.3% | -20.6% | -11.2% | -4.9% | -0.3% | -2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Dowden Nathan JOff | President & COO | Sell | 15,000 | $15.33 | $230K | 198,588 | -0.25% | — |
| May 4, 2026 | Sethuraman NatarajanOff | President, Research & Develop. | Sell | 25,907 | $15.39 | $399K | 216,317 | -0.25% | — |
8-K · 2.02
!! High
Entrada Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Entrada Therapeutics reported quarterly earnings results via press release filing, providing investors with updated financial performance and operational metrics.
May 7
8-K
Entrada Therapeutics, Inc. -- 8-K Filing
Entrada Therapeutics received a positive Data Monitoring Committee recommendation to advance ELEVATE-44-201 to a higher 12 mg/kg dose, signaling clinical progress in 2026 that could strengthen the company's pipeline momentum.
Feb 26
Data updated apr 27, 2026 5:30am
· Source: massive.com